Prostate cancer: postsurgical radiation yields favorable long-term quality of life

  • Akthar AS & al.
  • Eur Urol
  • 18 May 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with prostate cancer, intensity-modulated radiation therapy (IMRT) after prostatectomy was associated with favorable long-term QoL and late toxicity.

Why this matters

  • Findings may help guide clinical decision-making in consideration of preserving QoL and limiting late toxicity.

Study design

  • Prospective cohort study of 199 consecutive patients with prostate cancer who received IMRT after prostatectomy.
  • Funding: None.

Key results

  • Median follow-up, 33 months.
  • QoL remained stable over time in all 5 domains with no decline at any point exceeding the minimally clinically important difference.
  • 8%-18% of patients experienced a small effect; 0%-8% had moderate effect in multidomain decline up to 84 months.
  • At 4 years, the rates of freedom from grade ≥2 genitourinary and gastrointestinal toxicity were 94% and 95%, respectively.
  • Functional erections were recovered in 59% of patients recovered at month 36.
  • At 4 years, no significant difference was seen in urinary continence and urinary function domains in patients who used 0, 1, or ≥2 pads/day at baseline.
  • Use of sexual aid was stable at 7 years vs baseline.
  • Factors associated with worse QoL: longer time to IMRT, higher BMI, older age, hormone therapy, dose, current tobacco use, and bladder volume receiving 70 Gy.

Limitations

  • Patients lost to follow-up.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit